Daratumumab requires additional monkey studies
Chapter 3. This is the story about the founding of Genmab and the development of the company’s lead asset, oncology drug daratumumab. This third installment is about how Genmab is forced to conduct additional toxicity studies to establish the safety of the drug.
BY LONNI LYNGE
In the spring of 2006, the German company TeGenero initiates a clinical trial with a CD28 antibody – a study that – although not directly linked to it - would turn out to have a huge impact on Genmab’s development of daratumumab.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Popping the cork
For abonnenter
”It’s a slam dunk”
For abonnenter
Management wants to kill off dara – more than once
For abonnenter
